Evidence map›Paper›PMID 23696786›Full record

ArticlePloS one2013

Factors associated with not testing for HIV and consistent condom use among men in Soweto, South Africa.

Sakhile Mhlongo, Janan Dietrich, Kennedy N Otwombe, Gavin Robertson, Thomas J Coates, Glenda Gray

Registry-linked trialAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06133686 (Implementing Oral), which is not on this map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06133686 phase3not yet recruitingnot on this mapstarted 2024, after this paper: background citation

Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan Africa: a Phase 3b, Open-label, Hybrid Type 2 Implementation and Effectiveness Trial

TypeinterventionalSponsorMRC/UVRI and LSHTM Uganda Research UnitRan2024 to 2027Enrolled400ConditionsHIVArmsTenofovir disoproxil fumarate/emtricitabine (TDF-FTC), cabotegravir (CAB-LA), Cabotegravir (CAB-LA), Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC)
3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. [HIV communication paradigms must be changed in Africa].Medecine tropicale et sante internationale · 2021
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sakhile MhlongoPerinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, Gauteng, South Africa. sak-hile@live.com
Janan Dietrich
Kennedy N Otwombe
Gavin Robertson
Thomas J Coates
Glenda Gray

Funding

HIV Prevention trials Network (HPTN) Coordinating and Operations CenterU01AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI VERMUND, STEN H. · 2006 to 2010
$72.7M
Leadership for HIV/AIDS Clinical Trials Networks; HIV Prevention Trials NetworkU01AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DONNELL, DEBORAH J · 2006 to 2010
$28.8M
Community-Based HIV VCT: South AfricaU01MH066701 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI COATES, THOMAS J. · 2003 to 2010
$24.3M
HIV Prevention Trials Network: Network LaboratoryU01AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI ESHLEMAN, SUSAN H · 2006 to 2010
$16.5M
Community-Based VCT: ZimbabweU01MH066702 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MORIN, STEPHEN F · 2003 to 2010
$13.4M
Community-Based VCT: TanzaniaU01MH066688 · NIMH · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI SWEAT, MICHAEL D · 2003 to 2010
$11.7M
Community-Based VCT: ThailandU01MH066687 · NIMH · JOHNS HOPKINS UNIVERSITY · PI CELENTANO, DAVID D. · 2003 to 2010
$9.8M
NIAID NIH HHS U01 AI068613NIAID NIH HHS U01AI068613NIAID NIH HHS U01 AI068617NIAID NIH HHS U01AI068617NIAID NIH HHS U01 AI068619NIAID NIH HHS U01AI068619NIMH NIH HHS U01 MH066687NIMH NIH HHS U01MH066687NIMH NIH HHS U01 MH066688NIMH NIH HHS U01MH066688NIMH NIH HHS U01 MH066701NIMH NIH HHS U01MH066701NIMH NIH HHS U01 MH066702NIMH NIH HHS U01MH066702
6 · The paper itself

Abstract

backgroundBesides access to medical male circumcision, HIV testing, access to condoms and consistent condom use are additional strategies men can use to prevent HIV acquisition. We examine male behavior toward testing and condom use.

objectiveTo determine factors associated with never testing for HIV and consistent condom use among men who never test in Soweto.

methodsA cross-sectional survey in Soweto was conducted in 1539 men aged 18-32 years in 2007. Data were collected on socio-demographic and behavioral characteristics to determine factors associated with not testing and consistent condom use.

resultsOver two thirds (71%) of men had not had an HIV test and the majority (55%, n = 602) were young (18-23). Of those not testing, condom use was poor (44%, n = 304). Men who were 18-23 years (aOR: 2.261, CI: 1.534-3.331), with primary (aOR: 2.096, CI: 1.058-4.153) or high school (aOR: 1.622, CI: 1.078-2.439) education, had sex in the last 6 months (aOR: 1.703, CI: 1.055-2.751), and had ≥1 sexual partner (aOR: 1.749, CI: 1.196-2.557) were more likely not to test. Of those reporting condom use (n = 1036, 67%), consistent condom use was 43% (n = 451). HIV testing did not correlate with condom use.

conclusionLow rates of both condom use and HIV testing among men in a high HIV prevalence setting are worrisome and indicate an urgent need to develop innovative behavioral strategies to address this shortfall. Condom use is poor in this population whether tested or not tested for HIV, indicating no association between condom use and HIV testing.

Indexed as

CondomsAdolescentAdultHIV InfectionsHIV SeropositivityHumansMaleSafe SexSouth AfricaYoung Adult

Identifiers

PMID23696786
PMCPMC3656000

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.